These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Allosteric inhibitors of HMG-CoA reductase, the key enzyme involved in cholesterol biosynthesis. Haber A; Abu-Younis Ali A; Aviram M; Gross Z Chem Commun (Camb); 2013 Dec; 49(93):10917-9. PubMed ID: 23958894 [TBL] [Abstract][Full Text] [Related]
11. Venomics in medicinal chemistry. Dutertre S Future Med Chem; 2014 Oct; 6(15):1609-10. PubMed ID: 25406000 [No Abstract] [Full Text] [Related]
12. Discovery and quantitative structure-activity relationship study of lepidopteran HMG-CoA reductase inhibitors as selective insecticides. Zang YY; Li YM; Yin Y; Chen SS; Kai ZP Pest Manag Sci; 2017 Sep; 73(9):1944-1952. PubMed ID: 28247468 [TBL] [Abstract][Full Text] [Related]
13. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Istvan ES Am Heart J; 2002 Dec; 144(6 Suppl):S27-32. PubMed ID: 12486413 [TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment. Chen JB; Chern TR; Wei TT; Chen CC; Lin JH; Fang JM J Med Chem; 2013 May; 56(9):3645-55. PubMed ID: 23570542 [TBL] [Abstract][Full Text] [Related]
15. Discovery of a new class of HMG-CoA reductase inhibitor from Polyalthia longifolia as potential lipid lowering agent. Sashidhara KV; Singh SP; Srivastava A; Puri A; Chhonker YS; Bhatta RS; Shah P; Siddiqi MI Eur J Med Chem; 2011 Oct; 46(10):5206-11. PubMed ID: 21872367 [TBL] [Abstract][Full Text] [Related]
16. Medicinal Chemistry - XXth International Symposium. Lead finding strategies and kinase selectivity. Rotella DP IDrugs; 2008 Nov; 11(11):774-8. PubMed ID: 18988116 [No Abstract] [Full Text] [Related]
17. Exploration of natural product ingredients as inhibitors of human HMG-CoA reductase through structure-based virtual screening. Lin SH; Huang KJ; Weng CF; Shiuan D Drug Des Devel Ther; 2015; 9():3313-24. PubMed ID: 26170618 [TBL] [Abstract][Full Text] [Related]
18. High throughput discovery of heteroaromatic-modifying enzymes allows enhancement of novobiocin selectivity. Patel SM; de la Fuente M; Ke S; Guimarães AM; Oliyide AO; Ji X; Stapleton P; Osbourn A; Pan Y; Bowles DJ; Davis BG; Schatzlein A; Yang M Chem Commun (Camb); 2011 Oct; 47(38):10569-71. PubMed ID: 21863200 [TBL] [Abstract][Full Text] [Related]
19. Three-dimensional quantitative structure (3-D QSAR) activity relationship studies on imidazolyl and N-pyrrolyl heptenoates as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibitors by comparative molecular similarity indices analysis (CoMSIA). Thilagavathi R; Kumar R; Aparna V; Sobhia ME; Gopalakrishnan B; Chakraborti AK Bioorg Med Chem Lett; 2005 Feb; 15(4):1027-32. PubMed ID: 15686906 [TBL] [Abstract][Full Text] [Related]
20. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis. Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]